FDC
413.80
+5.65(+1.38%)
Market Cap₹- Cr
PE Ratio-
IndustryHealthcare
Company Performance:
1D+1.38%
1M-10.07%
6M-5.65%
1Y-18.53%
5Y+19.84%
View Company Insightsright
More news about FDC
07Aug 25
FDC Limited Reports Robust Q1 Performance with 33% Profit Growth
FDC Limited announced impressive Q1 financial results, with consolidated revenue reaching Rs. 648.41 crore and net profit at Rs. 121.35 crore. The company saw a 2.9% increase in standalone revenue and a 33% rise in consolidated net profit compared to the same quarter last year. The Board also approved the reappointment of Mr. Ashok A. Chandavarkar as Executive Director for a five-year term starting March 1, 2026, subject to shareholder approval.
07Aug 25
FDC Reports Steady Q1 Performance with Marginal Revenue Growth
FDC Limited's Q1 financial results show a steady performance. The company maintained a consolidated net profit of ₹120.00 crore, identical to last year's Q1. Revenue slightly increased to ₹650.00 crore from ₹640.00 crore, marking a 1.56% year-over-year growth. However, EBITDA decreased to ₹140.00 crore from ₹146.00 crore, with the EBITDA margin compressing to 21.54% from 22.81% year-over-year.
28May 25
FDC Reports Mixed Q4 Results: Revenue Up, Profit Down
FDC Limited's Q4 financial results show a 6.49% year-over-year revenue increase to ₹4.92 billion. However, profitability declined with EBITDA falling 4.12% to ₹539.80 crore and net profit decreasing 16.48% to ₹386.70 crore. The EBITDA margin compressed to 10.97% from 12.19% in the previous year.
30Apr 25
FDC Limited Approves Rs 140 Crore Expansion of Liquid Oral Facility at Sinnar Plant
FDC Limited has approved a Rs 140 crore expansion plan for its liquid oral facility at the Sinnar plant. The project will add 77,000 KL per annum to production capacity, to be completed in 18-24 months. Funded through internal accruals, this expansion aims to meet high capacity utilization (70-80%) and growing market demand. The investment is expected to strengthen FDC's manufacturing infrastructure and market position in the pharmaceutical sector.
FDC
413.80
+5.65
(+1.38%)
1 Year Returns:-18.53%
Industry Peers
Piramal Pharma
185.27
(+0.22%)
Zydus Life Science
942.70
(+0.67%)
Abbott
29,240.00
(-1.91%)
Zim Laboratories
71.32
(-2.57%)
Zota Healthcare
1,604.00
(-1.64%)
Supriya Lifescience
746.10
(-0.09%)
Sequent Scientific
216.12
(-2.39%)
IPCA Laboratories
1,429.30
(+0.61%)
Cohance Lifesciences
545.60
(-1.30%)